Skip to content

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Atypical Hemolytic-Uremic Syndrome

Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.

null

Conditions de participation

  • Sexe:

    ALL
  • Âges admissibles:

    0 and up

Critères de participation

Inclusion Criteria:

* Male or female patients of any age, including minors, who have been diagnosed with aHUS
* Patients with or without an identified complement pathogenic variant or anti-complement factor antibody
* Able to give written informed consent. Patient or patient's parent/legal guardian must be willing and able to given written informed consent and the patient (if minor) must be willing to give written informed assent \[if applicable as determined by the central Institutional Review Boards/Independent Ethics Committees (IRB/IEC)\].
* ADAMTS13 \> 5%, if performed.

Exclusion Criteria:

* Hemolytic Uremic Syndrome (HUS) only due to Shiga Toxin producing Escherichia coli (STEC).
* Unable to give written informed consent. Patient or patient's parent/legal guardian unable to give written informed consent. Patient (if minor) unable to give written informed assent (if applicable as determined by the central Institutional Review Boards/Independent Ethics Committees \[IRB/IEC\]).

Lieu de l'étude

Clinical Trial Site
Clinical Trial Site
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Licht

Clinical Trial Site
Clinical Trial Site
London, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Huang

Clinical Trial Site
Clinical Trial Site
Montréal, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Lapeyraque

Clinical Trial Site
Clinical Trial Site
Québec, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Philibert

Étude parrainée par
Alexion Pharmaceuticals, Inc.
Participants recherchés
Plus d'informations
ID de l'étude: NCT01522183